Chronic hepatitis B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Chronic hepatitis B infection is defined as HBsAg in the serum for six months. HBeAg and HBV DNA (measured using a polymerase chain reaction (PCR) assay) are viral replication and infectivity markers, whereas HBsAg is a hepatitis B viral infection marker. Cirrhosis, liver failure, hepatocellular carcinoma, and death are severe complications of chronic infection. HBV DNA can be found in the serum without HBeAg in a small percentage of patients. The "precore" mutant in these patients prevents completion and excretion of the "e" antigen despite active HBV DNA replication and is linked to progressive liver disease.

  • The risk for developing chronic hepatitis B after acute HBV infection is age-dependent; approximately 90% of infants become chronically infected, whereas only. Less than 5% of adults experience chronic illness.
  • If HBV transmission occurs at age ≤5 years, long‐term consequences such as chronic hepatitis, cirrhosis, or HCC would be significant problems.

Thelansis’s “Chronic hepatitis B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic hepatitis B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Chronic hepatitis B across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic hepatitis B Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Chronic hepatitis B– Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033